<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352663</url>
  </required_header>
  <id_info>
    <org_study_id>P3-GLR-IMSFDA-01</org_study_id>
    <nct_id>NCT01352663</nct_id>
  </id_info>
  <brief_title>Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients</brief_title>
  <official_title>An Open Label, Randomized Comparison of Wockhardt's Recombinant Insulin Analogue With Innovator's Glargine in Type 1 Diabetic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, randomized, parallel group comparison of the immunogenicity safety of
      Wockhardt's Recombinant Insulin Analogue with the innovator's Glargine in Type 1 diabetics
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate and compare the Immunogenicity Safety of Wockhardt's Recombinant Insulin Analogue
      with innovator's Glargine.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business strategy decision
  </why_stopped>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbAlc from baseline till the end of treatment period.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in immunogenic response.</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluating antibodies titre.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type I Diabetes</condition>
  <arm_group>
    <arm_group_label>Wockhardt's Insulin Analogue (Recomb)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lantus®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Wockhardt's Insulin Analogue (Recomb)</intervention_name>
    <description>Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.</description>
    <arm_group_label>Wockhardt's Insulin Analogue (Recomb)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lantus®</intervention_name>
    <description>Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.</description>
    <arm_group_label>Lantus®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who have been pre-diagnosed as cases of type-1 diabetes for a period not less
             than 1 year

          2. Male or Female Patients &gt;= 18 and =&lt; 55 years of age.

          3. Patients with BMI of 18.0 to 30.0 kg/m2

          4. Patients who are cooperative, reliable, and agree to have regular injections of
             insulin and are willing to comply with protocol procedures.

        Exclusion Criteria:

          1. A Patient who is pregnant or is currently breast-feeding.

          2. A Patient with history of severe hypoglycemia within the past year

          3. A Patient who is an employee of the Investigator, or a patient who has a direct
             involvement with the trial or other trials under the direction of the Investigator.

          4. Patients who are Hepatitis B or C positive on testing or have positive medical history
             of HIV at screening.

          5. Patients unlikely to comply with the study protocol e.g. unable to return periodically
             for subsequent visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Ashima Bhatia, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Wockhardt</affiliation>
  </overall_official>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>May 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2011</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type I Diabetes</keyword>
  <keyword>Wockhardt</keyword>
  <keyword>Insulin Analogue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

